Kisspeptin-10 is a decapeptide discovered in 1996 that acts as the 'master regulator' of the hypothalamic-pituitary-gonadal (HPG) axis. It stimulates the release of GnRH, which in turn activates LH and FSH, triggering endogenous testosterone production in men and estrogen production in women. It is an emerging tool for infertility, functional hypogonadism, libido, and post-steroid-cycle recovery.
| Target dose | Units | Volume |
|---|---|---|
| 333 mcg (low) | 10 UI | 0.10 mL |
| 500 mcg (standard) | 15 UI | 0.15 mL |
| 1 mg (high) | 30 UI | 0.30 mL |
| Dosis objetivo | Unidades | Volumen |
|---|---|---|
| 333 mcg (baja) | 10 UI | 0,10 mL |
| 500 mcg (estándar) | 15 UI | 0,15 mL |
| 1 mg (alta) | 30 UI | 0,30 mL |
| Dose cible | Unités | Volume |
|---|---|---|
| 333 mcg (faible) | 10 UI | 0,10 mL |
| 500 mcg (standard) | 15 UI | 0,15 mL |
| 1 mg (élevée) | 30 UI | 0,30 mL |
In research models, Kisspeptin-10 acts as the master regulator of the hypothalamic-pituitary-gonadal axis: it stimulates GnRH release, which activates LH and FSH and triggers endogenous testosterone in men and estrogen in women.
The 10 mg vial is reconstituted with 3 mL of bacteriostatic water, giving 3.33 mg/mL (≈ 33.3 mcg per UI). The water should be chilled only 3 minutes beforehand; injecting it down the inner wall and swirling gently keeps the solution clear.
The standard reference protocol is 500 mcg daily (15 UI / 0.15 mL) administered subcutaneously in the abdomen for 4–8 weeks, dosed once a day or every other day.
Kisspeptin-10 is studied as a modern alternative to HCG for post-cycle recovery: it activates the full HPG axis upstream rather than directly stimulating the testes, and it can be combined with Enclomiphene or Clomid in research protocols.